Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS201 in Advanced Malignant Tumors
NCT04956926Phase 1Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JS201 in advanced malignant solid tumor, lymphoma, Cervical Cancer (CC) and 3 more, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events up to 2 years and 2 more. Status: unknown.
02
Drugs
JS201
03
Conditions
advanced malignant solid tumorlymphomaCervical Cancer (CC)non-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04956926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956926.